Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Clinical trial NCT00328198 · COMPLETED
Trial details
- NCT number
- NCT00328198
- Sponsor
- Genzyme, a Sanofi Company
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2006-05-01
- Primary completion
- 2011-08-01
- Enrollment
- 86
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.